Emerging Designer Drug Predictions – New Computer Model
- "Designer drugs"-synthetic compounds created to mimic the effects of traditional illicit substances-present a unique challenge to law enforcement and public health.
- Researchers are now leveraging the power of computer modeling to proactively identify these emerging threats.
- Identifying illicit drugs typically relies on mass spectrometry, a technique that analyzes the unique chemical fingerprint - or mass spectrum - of a substance.
Closing the Net on “Designer Drugs” with Predictive Chemistry
Table of Contents
Published August 21, 2025
The Evolving Threat of Novel Psychoactive Substances
The illicit drug market is in constant flux. ”Designer drugs”-synthetic compounds created to mimic the effects of traditional illicit substances-present a unique challenge to law enforcement and public health. Thes substances are engineered to circumvent existing drug laws, often with unpredictable and hazardous consequences for users. Their constantly shifting chemical structures make traditional detection methods, reliant on matching known compounds, increasingly ineffective.
A Computational Solution: The Drugs of Abuse Metabolite Database (DAMD)
Researchers are now leveraging the power of computer modeling to proactively identify these emerging threats. A team, including high school student Jason Liang of Montgomery Blair High School, has developed a computational approach to predict the chemical structures and “fingerprints” of potential designer drugs and their metabolites - the substances created when the body processes the drug. This work culminates in the Drugs of Abuse Metabolite Database (DAMD), a resource poised to substantially enhance drug surveillance and improve patient care.
How Drug Identification Works – and Where It Falls Short
Identifying illicit drugs typically relies on mass spectrometry
, a technique that analyzes the unique chemical fingerprint
- or mass spectrum - of a substance. This fingerprint is based on the molecule’s shape, weight, and composition. When analyzing a urine sample, technicians compare the detected spectra to existing databases of known drugs and their metabolites. However, this system is reactive, not proactive. New designer drugs, by definition, lack entries in these databases, creating a critical gap in detection capabilities.
“It’s a chicken and the egg problem,” explains Tytus Mak, a statistician and data scientist at the National Institute of Standards and Technology (NIST). “How do you identify a substance you’ve never seen before?”
Building a Predictive Library
The DAMD project began with the recognition that computational modeling could potentially bridge this gap. Researchers Hani Habra (Michigan State University) and Tytus Mak initiated the project, and in the summer of 2024, brought on Jason Liang to contribute his programming and chemistry expertise. The team started with the existing mass-spectral database maintained by the Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), which contains data on over 2,000 confiscated drugs.Using computational methods, they then predicted nearly 20,000 additional chemical structures and their corresponding mass spectra, focusing on potential metabolites.
Validation and Real-world Application
Currently, the team is validating these predictions by comparing them to real-world data from human urine analyses.This involves matching the predicted spectra to those found in existing datasets of urine samples. A triumphant match indicates the plausibility of the predicted chemical structures. The next step involves comparing DAMD to already-collected real-world data to demonstrate its effectiveness in forensic toxicology.
The ultimate goal is to make DAMD a publicly available resource, supplementing existing drug databases and enabling faster, more accurate identification of designer drugs in urine samples. This has significant implications for medical care.
“If someone unknowingly ingested a substance laced with a fentanyl derivative,” Mak explains, “DAMD could help clinicians identify the presence of fentanyl-like metabolites in a toxicology report, allowing for more informed and potentially life-saving treatment decisions.”
